Nuwellis, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
NUWE$4.94+7.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| ASSETS · (Unaudited) | ||
| Current assets | ||
| Cash and cash equivalents | $2,083 | $1,085 |
| Accounts receivable | 1,559 | 1,493 |
| Inventories, net | 1,779 | 1,910 |
| Other current assets | 406 | 698 |
| Total current assets | 5,827 | 5,186 |
| Property, plant and equipment, net | 365 | 368 |
| Operating lease right-of-use asset | 237 | 293 |
| Intangible assets, net | 112 | — |
| Other assets | 420 | 271 |
| TOTAL ASSETS | $6,961 | $6,118 |
| LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities | ||
| Accounts payable and accrued liabilities | $2,429 | $2,226 |
| Accrued compensation | 852 | 460 |
| Current portion of operating lease liability | 265 | 261 |
| Deferred consideration from Rendiatech acquisition, current | 113 | — |
| Other current liabilities | 71 | 85 |
| Total current liabilities | 3,730 | 3,032 |
| Deferred consideration from Rendiatech acquisition, non-current | 200 | — |
| Warrant liabilities | 362 | 389 |
| Operating lease liability | — | 67 |
| Total liabilities | 4,292 | 3,488 |
| Commitments and contingencies | ||
| Mezzanine Equity | ||
| Series J Convertible Preferred Stock as of March 31, 2026 and December 31, 2025, par value $0.0001 per share; authorized 600,000 shares, issued and outstanding 147 and 137, respectively | 8 | 6 |
| Stockholders’ equity | ||
| Series A junior participating preferred stock as of March 31, 2026 and December 31, 2025, par value $0.0001 per share; authorized 30,000 shares, none outstanding | — | — |
| Series F convertible preferred stock as of March 31, 2026 and December 31, 2025, par value $0.0001 per share; authorized 18,000 shares, issued and outstanding 27 and 127 shares, respectively | — | — |
| Series F-1 convertible preferred stock as of March 31, 2026 and December 31, 2025, par value $0.0001 per share; authorized 100 shares, issued and outstanding 34 and 34 shares, respectively | — | — |
| Preferred stock as of March 31, 2026 and December 31, 2025, par value $0.0001 per share; authorized 39,352,000 shares, none outstanding | — | — |
| Common stock as of March 31, 2026 and December 31, 2025, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 2,635,718 and 1,686,217, respectively | — | — |
| Additional paid‑in capital | 323,506 | 318,928 |
| Accumulated other comprehensive income: | ||
| Foreign currency translation adjustment | 8 | 8 |
| Accumulated deficit | (320,853) | (316,312) |
| Total stockholders’ equity | 2,661 | 2,624 |
| TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY | $6,961 | $6,118 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.